publish revis model target follow
earn report late last week salient thought along relat
model adjust highlight
buy pt despit recent oper challeng optimist
new leadership restor growth improv profit go forward
aggress capit deploy offer sourc potenti upsid initi
guidanc final way believ neg revis cycl like see
scope number move higher execut improv year lower
ep forecast respect
account higher expect go-forward post-reform tax rate well modestli
lower core growth includ headwind drag distributor
equip inventori draw down larg impact us revenu dcf-
base pt move impli ev ufcf ebitda
downsid risk includ cad/cam competit execut delay new leadership
hold pt signific guidanc reduct two
straight quarter pathway back normal earn remain fluid continu
see multipl issu tabl share loss dental competit disrupt disrupt
erp transit intern sale forc turnov margin pressur anim health cfo
search none quick fix action plan leadership take time
implement dividend yield rel valuat may offer support
continu see mani near- long-term uncertainti get construct
yet cut ep forecast
respect assum roughli flat op growth dcf-base pt
move impli ep upsid risk includ faster-than-
expect rebound dental better anim health margin capit deploy
hold pt revenu miss consensu
shortfal larg due numer oper issu bio-refer lab unit
record revenu revers account reimburs receipt longer
expect receiv privat feder payor also see continu leadership turnov
red-flag meanwhil rayalde activ prescrib doc grew q/q
script trend rev mean product
still consum cash yr launch front test see
posit asp boost pama test volum growth
continu deceler y/i step back remain cautiou given
dwindl cash balanc on-going oper issu includ potenti liabil
sdni probe medicare/tricar bill key pipelin data read-out
cut rev respect account
lower rev remov varubi royal reduc rayalde expect all-in
sotp-bas target move upsid risk posit pipelin updat
posit medicar lcd better fundament
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
million except per share data
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash sheet metricsreceiv day day day convers interest earn -- -- -- -- -- net debt ttm valu per
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor total net product expens unconsol share share analysisgross gross analysisnet healthcar
million except per share data
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product expens share share analysisgross sg ebitda oper incom net growth analysisnet healthcar
million except per share data
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash net interest free cash sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor total total preciou net preciou product incom share share analysi net preciou metal gross research sg ebitda oper incom net growth analysissal net preciou gross sg oper incom net dilut
revenu
reimburs ramp asp
penetr
claro poc dx peak rev penetr
price base sotp/npv analysi
linger issu conjur legaci
question poor revenue/asset qualiti
on-going uncertainti reimburs front
diagnost asset continu see near-term
catalyst dramat chang debat
revenu
product
fda approv claro poc system
submiss fda
phase rayalde clinic trial higher strength
rayalde peak rev
claro test launch us peak rev
phase studi
payor contract
revenu
product flat
reimburs delay addl studi need
dilut equiti rais addl
page
pleas see import disclosur inform page report
share repurchas
divvi rel valuat may offer support
visibl remain low action new leadership may
take time implement still see mani near-
long-term uncertainti get construct yet
price impli ev ebitda
rebound us dental offic visit faster expect
benefit new erp
share repurchases/yr
deterior dental vet util trend weaker us
longer expect disrupt end sirona
e-commerc entrant erod market share pressur
synergi captur ahi acquisit
new dental equip distribut relationship
page
pleas see import disclosur inform page report
